Keros Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	246.72	3.55	0.15	-	20.1	-
Revenue Growth (YoY)	37798.31%	2250.99%	-	-	-	-
Cost of Revenue	154.96	173.63	135.26	87.27	55.14	33.86
Gross Profit	91.76	-170.08	-135.11	-87.27	-35.04	-33.86
Selling, General & Admin	45.27	40.75	34.83	27.53	21.33	12.8
Operating Expenses	45.27	40.75	34.83	27.53	21.33	12.8
Operating Income	46.49	-210.83	-169.94	-114.79	-56.37	-46.66
Interest Expense	-	-	-	-0	-0	-0.01
Interest & Investment Income	27.36	23.5	14.76	3.64	0.03	-
Currency Exchange Gain (Loss)	-1.04	-0.95	-0.21	-0.61	-	-
Other Non Operating Income (Expenses)	1.24	1.24	2.4	7.08	-0.38	1.13
Pretax Income	71.15	-187.05	-152.99	-104.68	-56.73	-45.53
Income Tax Expense	6.7	0.3	-	-	2.01	-0.17
Net Income	64.45	-187.35	-152.99	-104.68	-58.74	-45.36
Net Income to Common	64.45	-187.35	-152.99	-104.68	-58.74	-45.36
Shares Outstanding (Basic)	41	37	29	25	23	16
Shares Outstanding (Diluted)	41	37	29	25	23	16
Shares Change (YoY)	17.52%	27.13%	16.66%	8.17%	50.48%	566.41%
EPS (Basic)	1.59	-5.00	-5.20	-4.15	-2.52	-2.93
EPS (Diluted)	1.57	-5.00	-5.20	-4.15	-2.52	-2.93
Free Cash Flow	87.08	-162.8	-126.97	-71.3	-63.17	-37.19
Free Cash Flow Per Share	2.12	-4.35	-4.31	-2.83	-2.71	-2.40
Gross Margin	37.19%	-	-	-	-174.34%	-
Operating Margin	18.84%	-5938.96%	-112543.71%	-	-280.46%	-
Profit Margin	26.12%	-5277.55%	-101319.21%	-	-292.26%	-
Free Cash Flow Margin	35.30%	-4585.91%	-84087.42%	-	-314.29%	-
EBITDA	47.93	-209.6	-169.13	-114.12	-56	-46.38
EBITDA Margin	19.43%	-	-	-	-278.58%	-
D&A For EBITDA	1.44	1.23	0.82	0.67	0.38	0.28
EBIT	46.49	-210.83	-169.94	-114.79	-56.37	-46.66
EBIT Margin	18.84%	-	-	-	-280.46%	-
Revenue as Reported	246.72	3.55	0.15	-	20.1	-

Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q